18 results
6-K
EX-99.2
IFRX
InflaRx N.V.
5 Jun 24
InflaRx Hosts R&D Event Highlighting the Promise of INF904
5:07pm
% 9% Black box warning 1 SC injection 30 % remain symptomatic 5 Dupixent® (dupilumab) Phase 3 Anti-IL4/13 mAb 300 mg Q2w Placebo UAS7 (CFB) -16 -9 … of response No Black Box warning No hair or skin discoloration during and after treatment No issues with neutropenia or thrombocytopenia
6-K
IFRX
InflaRx N.V.
24 Feb 21
Current report (foreign)
4:16pm
authorities may require the addition of labeling statements, such as a “black box” warning or a contraindication;
we, or any future collaborators, may
6-K
EX-99.1
w9l7zm03blu3
21 May 20
Current report (foreign)
8:09am
6-K
EX-99.1
kuyr 0kss
7 Nov 19
Current report (foreign)
7:00am
6-K
EX-99.1
53a11vr77ube rqzecl3
14 Aug 19
Current report (foreign)
4:16pm
6-K
EX-99.1
et18yy5dk fqoflpg
23 May 19
Current report (foreign)
8:00am
20-F/A
3bpzc
29 Mar 19
Annual report (foreign) (amended)
4:23pm
6-K
EX-99.1
4nwlv muei
21 Nov 18
Current report (foreign)
8:34am
6-K
EX-99.1
g4qj1
9 Aug 18
Current report (foreign)
7:35am
6-K
EX-99.1
p01kdt
17 May 18
Current report (foreign)
7:45am
424B4
pioeeagcuptpq
7 May 18
Prospectus supplement with pricing info
4:47pm
F-1
jn9t8n
2 May 18
Registration statement (foreign)
7:10am
20-F
fe1 bthhv
29 Mar 18
Annual report (foreign)
12:00am
- Prev
- 1
- Next